Dominic Stone
Cyclic adenosine monophosphate (cAMP) is a well-researched second messenger molecule that has been shown to play a key role in the relaxation of airway smooth muscle (ASM) cells. Elevating intracellular cAMP levels is a common pharmacological intervention for the management of asthma and chronic obstructive pulmonary disease (COPD). This is achieved through the use of adrenaline, which activates β-2-adrenoceptors, and caffeine, which acts as a phosphodiesterase inhibitor to prevent cAMP degradation. The inhibitory effect of increased cAMP levels on ASM contraction is thought to be mediated by multiple mechanisms, including cAMP-dependent protein kinase (PKA) activation, PKA-independent activation of exchange proteins, and the reduction of intracellular calcium concentrations.
| Characteristics | Values |
|---|---|
| Increased cAMP | Causes smooth muscle relaxation |
| Contractile state of smooth muscle cells | Determined by the frequency of Ca2+ oscillations |
| cAMP-elevating agents | Cause a reduction in the frequency of Ca2+ oscillations |
| cAMP-mediated inhibition | Affects the IP3 receptor |
| cAMP-dependent PKA activation | Causes smooth muscle relaxation |
| PKA-independent activation of exchange proteins | Causes smooth muscle relaxation |
| Decrease of intracellular calcium concentrations | Causes smooth muscle relaxation |
| cAMP-mediated relaxation | Unaffected by L-type Ca2+ channel blocker, nifedipine |
| cAMP-elevating agents | Reduce ASM Ca2+ sensitivity |
| cAMP-mediated relaxation | Achieved by decreasing Ca2+ oscillation frequency |
| cAMP | Inhibits proliferation of VSMCs |
| cAMP | Plays a key role in controlling ciliary beat frequency |
| cAMP | Suppresses pro-inflammatory activity of immune and inflammatory cells |
| cAMP | Inhibits contraction of airway smooth muscle |
Explore related products
What You'll Learn
Increased cAMP levels lead to smooth muscle relaxation
Smooth muscle relaxation is a critical process in maintaining the health of the human body. It is particularly important in the management of asthma and chronic obstructive pulmonary disease (COPD). Increased levels of cyclic adenosine monophosphate (cAMP) in the body lead to smooth muscle relaxation.
CAMP is a second messenger molecule that plays a key role in signal transduction pathways. It is produced from ATP by adenylyl cyclase (AC) enzymes. In smooth muscle cells, the Gs-protein coupled pathway stimulates adenylyl cyclase, leading to increased cAMP production. This increased cAMP level inhibits the contraction of smooth muscle cells, resulting in relaxation.
The inhibitory effect of cAMP on smooth muscle contraction is mediated through multiple mechanisms. One key mechanism is the activation of cAMP-dependent protein kinase A (PKA). PKA phosphorylates and inhibits myosin light chain kinase (MLCK), which is responsible for initiating muscle contraction by phosphorylating myosin. By inhibiting MLCK, cAMP prevents the phosphorylation of myosin and subsequent contraction of the smooth muscle.
Another mechanism by which cAMP promotes smooth muscle relaxation is through the activation of exchange proteins such as Epac. Epac activation leads to the down-regulation of RhoA activity and the increase of Rap1 or Rac1 activities, resulting in cell relaxation. Additionally, cAMP can also decrease intracellular calcium concentrations, which contributes to smooth muscle relaxation.
Furthermore, cAMP-elevating agents have been shown to reduce the frequency of Ca2+ oscillations in smooth muscle cells, leading to relaxation. This reduction in Ca2+ oscillations is induced by a cAMP-mediated inhibition of the IP3 receptor. The decrease in Ca2+ oscillation frequency correlates with the extent of smooth muscle relaxation and is concentration-dependent. These cAMP-elevating agents, such as isoproterenol, forskolin, and 8-bromo-cAMP, have been effective in inducing smooth muscle relaxation and are used in the management of asthma and COPD.
Malaria's Muscle Pain: Understanding the Link
You may want to see also
Explore related products
cAMP-mediated inhibition of the IP3 receptor
The contractile state of airway smooth muscle cells (SMCs) in response to agonists is determined by the frequency of Ca2+ oscillations occurring within the SMCs. Agents that increase cAMP, such as isoproterenol (ISO), forskolin (FSK), and 8-bromo-cAMP, have been shown to induce relaxation of contracted airways and a reduction in the frequency of Ca2+ oscillations within the SMCs. This decrease in Ca2+ oscillation frequency is correlated with the extent of airway relaxation and is concentration-dependent.
The relaxant effect of cAMP-elevating agents on airway SMCs is achieved by decreasing the Ca2+ oscillation frequency by reducing internal Ca2+ release through IP3 receptors. The IP3 receptor, or inositol 1,4,5-trisphosphate receptor (IP3R), is a ubiquitous intracellular messenger that interacts with cAMP. While the molecular details mediating the action of cAMP require further investigation, it is proposed that cAMP inhibits the IP3R and reduces the open probability of the receptor. Additionally, cAMP may modify the Ca2+ sensitivity of the IP3R.
The role of cAMP in SMC relaxation has been confirmed by various studies. For example, in permeabilized DT40 cells expressing IP3R2, cAMP increased channel activity and potentiated Ca2+ release evoked by IP3. Furthermore, cAMP delivery to IP3R2s within signalling junctions directly potentiates their responses to IP3. This suggests that cAMP can directly sensitize IP3R subtypes to IP3.
The regulation of IP3 receptors by cAMP is complex and involves interactions with other proteins and signalling pathways. For instance, phosphorylation of IP3R by cAMP-dependent protein kinase (PKA) enhances IP3-evoked Ca2+ release through IP3R1 and IP3R2. Additionally, IRAG (IP3R-associated cGMP kinase substrate) expression may influence the regulation of IP3 receptors by blocking phosphorylation of IP3R1 by PKA. These interactions highlight the intricate nature of cAMP-mediated inhibition of the IP3 receptor and its role in SMC relaxation.
Neurotransmitters: Sparking Muscle Movement
You may want to see also
Explore related products
cAMP elevating agents reduce ASM Ca2+ sensitivity
The contractile state of airway smooth muscle cells (SMCs) is determined by the frequency of Ca2+ oscillations occurring within the SMCs. Agents that increase cAMP, such as isoproterenol (ISO), forskolin (FSK), and 8-bromo-cAMP, have been shown to induce relaxation of contracted airways by reducing the frequency of Ca2+ oscillations within the SMCs. This reduction in Ca2+ oscillation frequency is concentration-dependent and correlates with the extent of airway relaxation.
These cAMP-elevating agents are used in the management of asthma and chronic obstructive pulmonary disease (COPD) to relax airway smooth muscle and open the airways. The earliest asthma medications that increase cAMP include adrenaline and caffeine. More recently, combinatorial therapies that include glucocorticoids and cAMP elevating agents have been suggested to have additive and potentially synergistic effects.
The relaxation effect of cAMP-elevating agents on SMCs is achieved by decreasing the Ca2+ oscillation frequency and reducing internal Ca2+ release through IP3 receptors. This reduction in internal Ca2+ release is mediated by the inhibition of Ni2+- and La3+- sensitive Ca2+ channels. Additionally, cAMP-elevating agents have been shown to inhibit both PI hydrolysis and Ca2+ mobilization, further contributing to the reduction of Ca2+ sensitivity in SMCs.
Several studies have demonstrated that cAMP-elevating agents reduce ASM Ca2+ sensitivity. This reduction in Ca2+ sensitivity is a result of the inhibition of Ca2+-activated K+ channels and the reduced ability of IP3 to release Ca2+ in SMCs. These mechanisms contribute to the overall relaxation of contracted airways by reducing the contractile state of SMCs.
Activating the Levator Scapulae: Understanding Shoulder Action
You may want to see also
Explore related products
cAMP inhibits proliferation of VSMCs
Cyclic adenosine monophosphate (cAMP) is a second messenger that plays a crucial role in inhibiting the proliferation of vascular smooth muscle cells (VSMCs). This inhibition of VSMC proliferation is essential for maintaining vascular homeostasis and preventing pathological conditions such as restenosis, vein graft intimal thickening, and atherogenesis.
The anti-mitogenic properties of cAMP in VSMCs have been recognized for several years, but the underlying signalling mechanisms have only recently been elucidated. cAMP exerts its inhibitory effects on VSMC proliferation by modulating various cellular processes and pathways. One of the key mechanisms involves the inhibition of G1-S phase cell cycle progression. cAMP inhibits the expression of cyclins and prevents the Skp2-mediated degradation of cyclin-dependent kinase inhibitors, thereby blocking the cell cycle progression and subsequent proliferation of VSMCs.
Additionally, cAMP elevating agents, such as isoproterenol, forskolin, and 8-bromo-cAMP, have been shown to induce relaxation of airway SMCs. This relaxation is achieved by reducing the frequency of Ca2+ oscillations within the SMCs. The decrease in Ca2+ oscillation frequency is concentration-dependent and is associated with the extent of airway relaxation. Furthermore, cAMP-mediated inhibition of the IP3 receptor contributes to the reduction in Ca2+ oscillations, leading to SMC relaxation.
The cAMP effectors, Protein Kinase A (PKA) and Exchange Protein Activated by cAMP (EPAC), play a crucial role in inhibiting VSMC proliferation. They act synergistically to induce Cyclic-AMP Response Element Binding protein (CREB) activity and inhibit members of the RhoGTPases. This results in remodelling of the actin cytoskeleton, which is essential for controlling proliferation by modulating the activity of transcription factors that regulate genes required for proliferation.
Moreover, cAMP has been shown to inhibit collagen I synthesis induced by fetal calf serum and TGF-β. This inhibition of collagen synthesis may contribute to the overall inhibition of VSMC proliferation and migration, as collagen I is known to regulate these processes in vascular lesions.
Azithromycin and Muscle Pain: What's the Link?
You may want to see also
Explore related products
cAMP-dependent PKA activation
Cyclic adenosine monophosphate (cAMP) is a second messenger that plays a pivotal role in cell signalling and regulates many physiological and pathological processes. cAMP can regulate the transcription of various target genes, mainly through protein kinase A (PKA) and its downstream effectors such as cAMP-responsive element-binding protein (CREB).
Protein kinase A (PKA) is a family of serine-threonine kinases whose activity is dependent on cellular levels of cyclic AMP (cAMP). PKA is also known as cAMP-dependent protein kinase (EC 2.7.11.11). PKA has several functions in the cell, including the regulation of glycogen, sugar, and lipid metabolism.
PKA is the most important effector for cAMP, mediating numerous physiological responses elicited by G-protein-coupled receptors. PKA subunits show a wide cellular distribution in the brain and affect many neuronal functions via phosphorylation of a broad range of neuronal substrates. These include integral neurotransmitter receptors, such as AMPA receptor subunits, GABAA receptors, and D1 dopamine receptors, and a variety of Ca2+- , K+- and Na+-channels.
The generation of cAMP is regulated in a G-protein-dependent manner by adenylyl cyclase (AC) or in a G-protein-independent manner by soluble adenylyl cyclase (sAC). The degradation of cAMP is regulated by phosphodiesterases (PDEs). cAMP signalling pathways can regulate ion channels, Epac, and PKA.
When a G-protein-coupled receptor (GPCR) is activated by its extracellular ligand, a conformational change is induced in the receptor that is transmitted to an attached intracellular heterotrimeric G-protein complex by protein domain dynamics. The Gs alpha subunit of the stimulated G-protein complex exchanges GDP for GTP in a reaction catalysed by the GPCR and is released from the complex. The activated Gs alpha subunit then binds to and activates an enzyme called adenylyl cyclase, which catalyses the conversion of ATP into cAMP, directly increasing the cAMP level. Four cAMP molecules can bind to the two regulatory subunits of PKA. This is done by two cAMP molecules binding to each of the two cAMP binding sites (CNB-B and CNB-A), which induces a conformational change in the regulatory subunits of PKA, causing the subunits to detach and unleash the two now activated catalytic subunits. The liberated catalytic subunits can then catalyse the transfer of ATP terminal phosphates to protein substrates at serine or threonine residues. This phosphorylation usually results in a change in the activity of the substrate.
In summary, increased cAMP levels can lead to smooth muscle relaxation by multiple mechanisms, including cAMP-dependent PKA activation.
Thyroid and Muscle Twitching: Is There a Link?
You may want to see also
Frequently asked questions
cAMP, or 3’-5’-Cyclic adenosine monophosphate, is a second messenger molecule that plays a role in various physiological and pathophysiological processes.
Increased cAMP levels lead to smooth muscle relaxation by activating effector molecules such as cAMP-dependent protein kinase (PKA) and Epac. cAMP inhibits calcium-calmodulin activation of myosin light chain kinase (MLCK), which causes contraction. It also reduces intracellular calcium concentrations and associated signalling.
Adrenaline, caffeine, isoproterenol, forskolin, and 8-bromo-cAMP are all cAMP-elevating agents.
cAMP-elevating agents are used to manage asthma and COPD by relaxing airway smooth muscle and opening the airways.
